Abstract 2714
Background
Although tumor-infiltrating lymphocytes density is associated with increased response and improved outcomes in HER2+ breast cancer, BCR clonal diversity repertoire could provide a more informative measure of an individual’s immune-mediated anti-tumor response. In this study, we focus on the specific role of B-cell gene-expression signatures and BCR repertoire as predictive and prognostic biomarkers in CALGB 40601, a neoadjuvant study of single vs. dual (trastuzumab + lapatinib) HER2 targeting with paclitaxel.
Methods
Gene expression profiling by mRNA sequencing was performed on 265 pre-treatment samples and signature scores were calculated by determining the median expression of all genes in a signature. BCR repertoire analysis using V’DJer was assessed on 256 of the samples. The predictive and prognostic value of clinical parameters, signature scores and BCR diversity metrics was tested in a univariate analysis for pathologic complete response (pCR) and event-free survival (EFS).
Results
Of the >600 expression signatures tested, 10 were significantly associated with both pCR and EFS. Five immune-related signatures were associated with higher pCR and better outcome: a T-helper signature (OR = 5.1, HR = 0.22, both p < 0.05), 2 IgG signatures (OR = 2.2 and 1.72, HR = 0.61 and 0.70 respectively, all p < 0.05) and 2 B-cell signatures (OR = 1.63 and 1.27, HR = 0.74 and 0.81 respectively, all p < 0.05). Patients with a high IgG-signature showed a significant higher pCR rate when treated with a trastuzumab combination regimen (58% vs. 34%, p 0.001). The Ig heavy chain γ (IGHG) was the most abundant isotype (median counts = 4,800). Patients without assembled IGHG or a high evenness showed a significantly lower pCR rate (27% vs. 54%, p < 0.001 and 12% vs. 59%, p < 0.001, respectively). Patients with high IGHG counts also showed a significant EFS benefit at 5 years (log rank 0.03).
Conclusions
B-cell gene expression signatures have a relevant predictive and prognostic value in CALGB 40601. The clinical implementation of these biomarkers could help us to design new neoadjuvant treatment strategies for HER2+ breast cancer.
Clinical trial identification
NCT007708.
Editorial acknowledgement
Legal entity responsible for the study
Alliance of Clinical Trials.
Funding
U10CA180821, U10CA180882, U24CA196171, P50-CA58223, GSK, SPORE, BCRF and SEOM.
Disclosure
C.M. Perou: Advisory / Consultancy, Shareholder / Stockholder / Stock options: BioClassifier LLC; Licensing / Royalties, Inventor on patent applications: Breast PAM50. All other authors have declared no conflicts of interest.
Resources from the same session
4736 - Prognostic value of tumor infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy
Presenter: Ji Hyun Park
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
6136 - Clinical Outcomes by Chemotherapy Regimen in Patients with RS 26-100 in TAILORx
Presenter: Joseph Sparano
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
4667 - Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
Presenter: Michael Untch
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Proffered Paper - Breast cancer, early stage - Invited Discussant LBA18 and LBA19
Presenter: Antonio Llombart Cussac
Session: Proffered Paper - Breast cancer, early stage
Resources:
Slides
Webcast
Proffered Paper - Breast cancer, early stage - Invited Discussant 174O and 175O
Presenter: Christos Sotiriou
Session: Proffered Paper - Breast cancer, early stage
Resources:
Slides
Webcast